Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label study of TAK-228 in East Asian adults with advanced solid tumors
jRCT2080223766Phase 1Completed
- Sponsor
- Takeda
- Start
- Jan 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of sapanisertib in advanced nonhematological malignancy and Non-hematologic malignancy (2 arms), sponsored by Takeda. Primary endpoints: Safety and tolerability of TAK-228 and Pharmacokinetics of TAK-228. Started Jan 2018; status: completed.
02
Drugs
sapanisertib
03
Conditions
advanced nonhematological malignancyNon-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080223766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223766.